國家衛生研究院 NHRI:Item 3990099045/2958

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Conference Papers/Meeting Abstract > Item 3990099045/2958

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2958

Title:	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
Authors:	Chan, ATC;Hsu, MM;Goh, BC;Hui, EP;Liu, TW;Millward, MJ;Hong, RL;Whang-Peng, J;Ma, BBY;To, KF;Mueser, M;Amellal, N;Lin, X;Chang, AY
Contributors:	National Institute of Cancer Research
Abstract:	Purpose To evaluate efficacy and toxicity of cetuximab plus carboplatin in recurrent or metastatic nasopharyngeal carcinoma (NPC) resistant to platinum treatment. Patients and Methods A multicenter, open-label, single-arm, phase 11 study in patients with epidermal growth factor receptor-expressing NPC who progressed on or within 12 months after termination of platinum-based chemotherapy for recurrent or metastatic disease. Cetuximab was administered at an initial dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2). Carboplatin area under the curve 5 was administered every 3 weeks up to a maximum of eight cycles. Results Sixty patients were enrolled (46 males, 14 females; median age, 44.5 years; range, 23 to 64 years), and all patients were included in the intent-to-treat and safety analyses. Of the 59 patients assessable for efficacy, there were seven partial responses (11.7%), 29 patients (48.3%) with stable disease, and 23 patients (38.3%) with progressive disease, giving an overall response rate of 11.7% (95% Cl, 4.8% to 22.6%). The median time to progression was 81 days in all patients and was longest in the group of patients with a confirmed response (173 days). The median overall survival time was 233 days in all patients. Six patients (10%) experienced serious treatment-related adverse events. Grade 3 or 4 toxicities occurred in 31 patients (51.7%); of these patients, only 19 (31.7%) were considered to have toxicity related to cetuximab. Conclusion Cetuximab in combination with carboplatin demonstrates clinical activity and an acceptable safety profile in heavily pretreated patients with recurrent or metastatic NPC who had previously experienced treatment failure with platinum-based therapy.
Keywords:	Oncology
Date:	2005-05-20
Relation:	Journal of Clinical Oncology. 2005 May;23(15):3568-3576.
Link to:	http://dx.doi.org/10.1200/JCO.2005.02.147
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000229352400038
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=20644435370
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Conference Papers/Meeting Abstract [Tsang-Wu Liu] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
000229352400038.pdf		381Kb	Adobe PDF	1282	View/Open

Loading...